Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

BACKGROUND: Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). To date, no blood biomarkers have been identified in NSCLC t...

Descripción completa

Detalles Bibliográficos
Autores principales: Soyano, Aixa E., Dholaria, Bhagirathbhai, Marin-Acevedo, Julian A., Diehl, Nancy, Hodge, David, Luo, Yan, Manochakian, Rami, Chumsri, Saranya, Adjei, Alex, Knutson, Keith L., Lou, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251165/
https://www.ncbi.nlm.nih.gov/pubmed/30470260
http://dx.doi.org/10.1186/s40425-018-0447-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251165/
https://www.ncbi.nlm.nih.gov/pubmed/30470260
http://dx.doi.org/10.1186/s40425-018-0447-2

Ejemplares similares